Deflazacort Use in Pregnancy
Deflazacort should only be used during pregnancy if the potential benefit clearly justifies the potential risk to the fetus, and it is not routinely indicated for pregnancy-related conditions. The FDA label explicitly states this risk-benefit framework, and there is concerning evidence that deflazacort may actually decrease the likelihood of achieving clinical pregnancy 1.
Key Evidence from FDA Labeling
The FDA drug label for deflazacort provides critical guidance 1:
- No adequate and well-controlled studies exist with deflazacort in pregnant women to inform drug-associated risks
- Deflazacort readily crosses the placenta, exposing the fetus to the medication
- Known adverse developmental outcomes include:
- Orofacial clefts (cleft lip with or without cleft palate): increased risk from 1/1,000 to 3-5/1,000 infants
- Intrauterine growth restriction
- Decreased birth weight (dose-related)
- Infants born to mothers receiving substantial doses should be carefully observed for signs of hypoadrenalism
Clinical Research Findings
A retrospective cohort study of kidney transplant patients found deflazacort use was significantly associated with decreased odds of clinical pregnancy (P = 0.02) and was the only remaining factor that could hinder pregnancy success in Cox regression analysis (P = 0.03) 2. This suggests deflazacort may have unique negative effects on pregnancy outcomes compared to other corticosteroids.
Preferred Corticosteroid Alternatives in Pregnancy
The 2025 EULAR guidelines provide clear direction for corticosteroid use in pregnancy 3:
- Prednisone and prednisolone are the preferred corticosteroids during pregnancy
- These agents are not associated with increased major birth defects when used to control active disease
- Target dose: ≤5 mg/day when possible, with tapering to this maintenance dose
- Higher doses should be used only when maternal disease control requires it, weighing maternal-fetal complications
Important Caveats
Dose-related risks with all corticosteroids at higher doses include:
- Pregnancy-associated osteoporosis
- Gestational diabetes
- Serious maternal infections
- Preterm birth
Critical distinction: While deflazacort is FDA-approved for Duchenne muscular dystrophy in pediatric patients ≥5 years, this does not translate to safety or indication during pregnancy. The drug's primary indication is for a specific neuromuscular condition, not pregnancy-related disorders.
Clinical Algorithm
If corticosteroid therapy is needed during pregnancy:
- Choose prednisone or prednisolone over deflazacort
- Target maintenance dose ≤5 mg/day
- Use the lowest effective dose for the shortest duration
If patient is already on deflazacort and becomes pregnant:
- Consider switching to prednisone/prednisolone if clinically feasible
- Consult with maternal-fetal medicine and the treating specialist
- Weigh the risks of switching medications against continuing deflazacort
For severe, refractory maternal disease:
- IV methylprednisolone pulses are preferred over oral deflazacort
- Consider pregnancy-compatible DMARDs or biologics as alternatives
Bottom line: Deflazacort is not indicated for routine use in pregnancy and should be avoided when safer corticosteroid alternatives (prednisone/prednisolone) are available 1, 2.